New York State Common Retirement Fund lifted its position in shares of Allergan PLC. (NYSE:AGN) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,110,487 shares of the company’s stock after acquiring an additional 44,834 shares during the quarter. New York State Common Retirement Fund owned 0.33% of Allergan PLC. worth $269,948,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Howard Hughes Medical Institute acquired a new stake in Allergan PLC. in the 2nd quarter valued at $103,000. Jacobi Capital Management LLC raised its position in Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after acquiring an additional 22 shares during the period. JNBA Financial Advisors raised its position in Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after acquiring an additional 12 shares during the period. Pacific Center for Financial Services raised its position in Allergan PLC. by 805.1% during the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after acquiring an additional 475 shares during the period. Finally, Ropes Wealth Advisors LLC raised its position in Allergan PLC. by 31.0% during the first quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock worth $137,000 after acquiring an additional 136 shares during the period. 82.03% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “New York State Common Retirement Fund Has $269.95 Million Holdings in Allergan PLC. (AGN)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/03/new-york-state-common-retirement-fund-has-269-95-million-holdings-in-allergan-plc-agn.html.

Shares of Allergan PLC. (NYSE:AGN) opened at 210.98 on Tuesday. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The firm has a market cap of $70.53 billion, a PE ratio of 6.43 and a beta of 1.15. The firm’s 50-day moving average price is $220.85 and its 200 day moving average price is $233.92.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.35 EPS. On average, equities research analysts forecast that Allergan PLC. will post $16.22 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.33%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

Allergan PLC. declared that its Board of Directors has initiated a stock repurchase plan on Monday, September 25th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

AGN has been the topic of several recent analyst reports. Wells Fargo & Company reaffirmed a “buy” rating on shares of Allergan PLC. in a report on Monday. Barclays PLC reissued an “equal weight” rating on shares of Allergan PLC. in a research note on Monday. UBS AG reissued a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a research note on Tuesday, September 26th. Credit Suisse Group restated an “outperform” rating and set a $266.00 price target (down previously from $286.00) on shares of Allergan PLC. in a research report on Tuesday, September 26th. Finally, Mizuho restated a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a research report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the stock. Allergan PLC. currently has an average rating of “Buy” and an average price target of $271.84.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.